This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It?

Biogen reported 2025 revenue of $9.9 billion, up just 2% year over year, while adjusted EPS fell 7% to $15.28. Newer products and label expansions such as Leqembi, high-dose Spinraza, Skyclarys, and Zurzuvae are helping, but management guidance still points to another year of sales decline in 2026. The article argues Biogen's longer-term recovery remains uncertain and that the stock is risky despite recent regulatory progress.

Analysis

BIIB is in a classic transition trap: the market is likely overpaying for optionality in newer assets while underestimating the duration of erosion in the legacy base. When a company’s near-term growth is constrained by mix deterioration and slower replenishment than investors expected, the stock tends to trade on pipeline proof points rather than headline approvals, so upside becomes lumpy and milestone-driven instead of operating-leverage driven. That favors competitors with cleaner growth trajectories and more visible capital allocation, especially within large-cap biotech where balance-sheet quality and recurring cash generation matter more than binary launch narratives.

The second-order issue is that Biogen’s newer products are still too small to offset a shrinking core, which creates a sequencing problem: every incremental commercial win gets absorbed by decline elsewhere. That makes label expansions helpful but not transformative unless they change prescribing behavior materially and quickly. In practice, the biggest beneficiary may be not Biogen but rival neurology and rare-disease names that can use Biogen’s stumble to win formulary attention, physician mindshare, and acquisition currency over the next 6-18 months.

Catalyst timing matters here. The stock can work on single-product execution over days or weeks, but the fundamental debate is a 12-24 month story about whether newer launches can compound fast enough before the legacy drag forces another reset. The tail risk is that management is implicitly asked to deliver multiple commercialization inflections simultaneously, which is rare in biotech; if any one of the new assets underperforms, consensus likely has to cut outer-year revenue and margin assumptions again.

The contrarian case is that the market may already be discounting a lot of bad news, so the stock is not necessarily a short on valuation alone. But the setup still looks asymmetric against buyers: you need near-flawless execution for a rerating, while downside only requires normal launch friction or further erosion in mature franchises. That is a poor risk/reward profile for long-only capital unless you are specifically underwriting a catalyst-rich, event-driven trade rather than a durable compounder.

Key Decisions for Investors

• Avoid initiating a fresh long in BIIB for a 6-12 month fundamental hold; the setup requires multiple positive execution surprises with limited margin for error, making the skew unattractive.
• If already long BIIB, reduce on strength into label-expansion or launch-related rallies and re-underwrite only after evidence of sustained prescription acceleration over 2-3 quarters.
• Pair trade: long a higher-quality large-cap biotech with cleaner growth visibility against short BIIB over the next 3-6 months; the relative-value expression is better than an outright short because BIIB still has event-driven upside.
• For event-driven investors, use call spreads rather than stock to express upside around discrete commercial catalysts; the stock likely needs a 12-18 month proof window, so defined-risk upside is superior to spot exposure.
• Monitor quarterly prescription trends and management guidance revisions closely; if consensus revenue is cut again within the next 1-2 quarters, the stock likely de-rates further despite incremental approvals.